Diphereline PR Indications/Uses

Prostate cancer: Treatment of locally advanced prostate cancer when used alone or as concomitant and adjuvant to radiotherapy.
Treatment of metastatic prostate cancer.
Patients who have not previously received hormone therapy show a more marked response to the treatment and response more frequently if the patient has not previously received another hormone treatment.
Genital and Extragenital Endometriosis (Stage I to Stage IV): Treatment should not be administered for more than 6 months. (see Adverse Reactions). It is not recommended to start a second treatment course with triptorelin or another GnRH analogue.
Precocious puberty (before 8 years in girls and 10 years in boys).
3.75 mg: Treatment of uterine fibromyomas prior to surgery: Associated with anaemia (haemoglobin less than or equal to 8 g/dl),
When a reduction in the size of the fibromyoma is necessary to facilitate or modify the surgical technique: endoscopic surgery, transvaginal surgery.
The treatment duration is restricted to 3 months.
3.75 mg: Breast cancer: As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy.